Concepts (95)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neuroendocrine Tumors | 4 | 2024 | 118 | 1.890 |
Why?
|
| Stomach Neoplasms | 5 | 2024 | 281 | 1.360 |
Why?
|
| Intestinal Neoplasms | 2 | 2024 | 64 | 1.090 |
Why?
|
| X-linked Nuclear Protein | 1 | 2024 | 9 | 0.980 |
Why?
|
| Co-Repressor Proteins | 1 | 2024 | 24 | 0.970 |
Why?
|
| Receptors, Peptide | 1 | 2024 | 22 | 0.970 |
Why?
|
| Molecular Chaperones | 1 | 2024 | 122 | 0.920 |
Why?
|
| Pancreatic Neoplasms | 3 | 2024 | 669 | 0.890 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2024 | 665 | 0.890 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2022 | 93 | 0.800 |
Why?
|
| Liver Neoplasms | 5 | 2024 | 754 | 0.700 |
Why?
|
| Cholangiocarcinoma | 4 | 2024 | 76 | 0.680 |
Why?
|
| Bile Duct Neoplasms | 4 | 2024 | 90 | 0.670 |
Why?
|
| Carcinoma, Hepatocellular | 4 | 2024 | 390 | 0.650 |
Why?
|
| Adenocarcinoma | 5 | 2023 | 1194 | 0.490 |
Why?
|
| Mutation | 3 | 2024 | 4137 | 0.470 |
Why?
|
| Thyroid Neoplasms | 3 | 2023 | 424 | 0.440 |
Why?
|
| Octreotide | 2 | 2024 | 23 | 0.420 |
Why?
|
| Appendiceal Neoplasms | 2 | 2024 | 31 | 0.410 |
Why?
|
| Embolization, Therapeutic | 2 | 2024 | 262 | 0.370 |
Why?
|
| Circulating Tumor DNA | 1 | 2024 | 47 | 0.220 |
Why?
|
| Yttrium Radioisotopes | 4 | 2024 | 58 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2022 | 146 | 0.220 |
Why?
|
| Radioisotopes | 1 | 2022 | 45 | 0.210 |
Why?
|
| Hepatectomy | 1 | 2024 | 170 | 0.210 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2022 | 15 | 0.200 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 6794 | 0.200 |
Why?
|
| Transplants | 1 | 2022 | 41 | 0.200 |
Why?
|
| Esophageal Neoplasms | 2 | 2020 | 332 | 0.190 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2020 | 14 | 0.190 |
Why?
|
| Coordination Complexes | 1 | 2020 | 20 | 0.180 |
Why?
|
| Humans | 19 | 2024 | 89157 | 0.170 |
Why?
|
| Hyperthermia, Induced | 1 | 2020 | 73 | 0.170 |
Why?
|
| ras Proteins | 1 | 2020 | 130 | 0.170 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2023 | 72 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 1 | 2020 | 184 | 0.160 |
Why?
|
| Aged | 7 | 2024 | 19119 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2022 | 2553 | 0.160 |
Why?
|
| Glucuronosyltransferase | 1 | 2020 | 186 | 0.160 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 195 | 0.160 |
Why?
|
| Radiosurgery | 1 | 2021 | 280 | 0.150 |
Why?
|
| Treatment Outcome | 7 | 2024 | 8217 | 0.150 |
Why?
|
| Prospective Studies | 2 | 2022 | 4281 | 0.140 |
Why?
|
| Middle Aged | 7 | 2024 | 25910 | 0.140 |
Why?
|
| Transcriptome | 1 | 2020 | 628 | 0.130 |
Why?
|
| Adult | 6 | 2024 | 26542 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2020 | 1265 | 0.130 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1177 | 0.120 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 967 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2021 | 1402 | 0.120 |
Why?
|
| Retrospective Studies | 6 | 2024 | 9022 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1665 | 0.120 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 1710 | 0.110 |
Why?
|
| Microspheres | 2 | 2023 | 108 | 0.110 |
Why?
|
| Male | 7 | 2024 | 42309 | 0.110 |
Why?
|
| Female | 7 | 2024 | 46078 | 0.100 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2021 | 76 | 0.090 |
Why?
|
| Positron-Emission Tomography | 2 | 2020 | 336 | 0.080 |
Why?
|
| Neoplasms | 1 | 2021 | 3037 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 2002 | 0.060 |
Why?
|
| Hypertrophy | 1 | 2024 | 67 | 0.060 |
Why?
|
| Liver Regeneration | 1 | 2024 | 36 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2023 | 72 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 209 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 134 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2024 | 193 | 0.050 |
Why?
|
| Tumor Burden | 1 | 2024 | 308 | 0.050 |
Why?
|
| Ipilimumab | 1 | 2022 | 61 | 0.050 |
Why?
|
| Capecitabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Pyridones | 1 | 2022 | 56 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2022 | 77 | 0.050 |
Why?
|
| Imidazoles | 1 | 2022 | 148 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 423 | 0.050 |
Why?
|
| Gastrectomy | 1 | 2021 | 69 | 0.050 |
Why?
|
| Cisplatin | 1 | 2022 | 617 | 0.050 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2020 | 58 | 0.040 |
Why?
|
| DNA Repair | 1 | 2022 | 362 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 224 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 1214 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 434 | 0.040 |
Why?
|
| Organometallic Compounds | 1 | 2020 | 134 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2020 | 895 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 860 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 285 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2020 | 561 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2024 | 1363 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2022 | 669 | 0.040 |
Why?
|
| Infant | 1 | 2023 | 3149 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1890 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 1424 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 1848 | 0.030 |
Why?
|
| Time Factors | 1 | 2024 | 5331 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2020 | 1429 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2020 | 2412 | 0.020 |
Why?
|